Skip to main content
OpenTrials
Completed

NCT Number: NCT06376773

Neoadjuvant Treatment Based on Gastric Cancer Molecular Subtyping.

Extensive research employing diverse omics methodologies has unveiled a varied landscape of gastric cancer (GC). Recent progress in next-generation sequencing and other genomic technologies has facilitated a more intricate exploration of GC at the molecular level. This study aimed to identify the most effective drug therapeutics for patients with the mesenchymal subtype of gastric cancer.Based on RNA-seq transcriptome, 234 patients were divided into four molecular subtypes: mesenchymal, immunogenic, metabolic, and classic.Our analysis has revealed that, for neoadjuvant therapy in advanced gastric cancer (AGC), the mesenchymal subtype stands out as the ideal patient population benefiting from Apatinib, without a concurrent increase in postoperative complications.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Advanced Gastric Cancer Multi-omics Analysis Neoadjuvant Therapy

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Fujian Medical University Union Hospital

Fuzhou, Fuji'an, 350000, China

About this study

The advent of immunotherapy and targeted therapies has recently provided new options for AGC treatment. However, not all patients benefit from immunotherapy or targeted therapy, resulting in unsatisfactory overall treatment outcomes during the perioperative period. An ineffective treatment imposes significant financial burden, causes drug-related side effects that deteriorate their quality of life, and potentially delays subsequent treatment.

Evaluate the objective response rate (ORR) of the combination of camrelizumb, apatinib, and neoadjuvant chemotherapy for the treatment of advanced gastric patient Median survival time (OS);

Disease free survival time (DFS);

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • diagnosed with gastric adenocarcinoma and received neoadjuvant therapy

Exclusion criteria

  • Patients with distant metastases, gastric stump cancer, or missing neoadjuvant chemotherapy data were excluded from the study.

Treatment and study plan

combination chemotherapy with Apatinib or Camrelizumab

Procedure

Apatinib, chemotherapy alone, Camrelizumab

Other names: mesenchymal, immunogenic, metabolic, classic

Primary outcomes

  1. overall survival

    Time frame: 2years

    overall survival

Secondary outcomes

  1. objective response rate

    Time frame: 6months

    objective response rate

Sponsors and collaborators

Lead sponsor

Fujian Medical University

Other

Registry information

Official study title

Neoadjuvant Treatment Based on Gastric Cancer Molecular Subtyping: Chemotherapy, Immunotherapy, or Targeted Therapy? -A Retrospective Real-World Data Analysis

Important dates

Study start
2022
Primary completion
2023
Study completion
2023
First posted
Apr 19, 2024
Registry last updated
Apr 19, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.